Groups
Main Sector
Investor Type
Service Provider Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Index
Countries
Reset

James Lovgren United States

ORIG3N is a biotech company based in Boston, MA. The scientific mission is to deliver a disease-modeling platform targeting rare genetically inherited diseases. By advancing screening projects using iPSC-derived differentiated cells and rapidly delivering the resulting data to inform therapeutic decisions, ORIG3N will replace trial & error guess work of treating disease and enable longer, healthier lives. 

Website:
www.orig3n.com
Main Sector
Biotech Subsector
Medtech Subsector
Indication
Technology Overview
ORIG3N specializes in the generation of patient specific iPSC-derived cardiomyocytes, neurons, and hepatocytes. We have also built a unique iPSCs bank, called Life Capsule, with fully consented samples from patients with various neurodegenerative and cardiac diseases. Utilizing the diverse patient population from Life Capsule, we are able to provide patient and disease specific cell models.
Management Team Highlights
Successful repeat entrepreneurs, the founding team has 60+ years of experience in life science. Robin Smith, the CEO has 3 prior successful exits - the most recent two were VC backed and both sold to publicly traded companies; provided 24:1 return and 74%IRR to prior investors.
James Lovgren
ORIG3N
LinkedIn logo CBO 

Kevin Lynch

AbbVie was founded by Abbott Laboratories in 213 and is based in Chicago IL. The firm partners with developmental-stage biotech companies and is actively seeking to in-license therapeutic assets. AbbVie generally seeks global rights to assets and will consider partnerships worldwide, the firm licenses assets opportunistically with no set rate of allocations. AbbVie also has a venture arm that makes equity investments AbbVie Venture & Early-Stage Collaborations.
Website:
www.abbvie.com
Investor Type
Sector Interest
Biotech Subsector
Indication
Biotech Phase of Development
Capital Structure Preference
Investment Stage Preference
AbbVie
Vice President Search and Evaluation